<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna Inc (NASDAQ: MRNA) is continuing to trade lower Monday amid news surrounding Merck & Co Inc’s (NYSE: MRK) oral COVID-19 treatment. Merck, and Ridgeback, on Friday announced its investigational oral antiviral molnupiravir reduced risk of hospitalization or death by about 50% versus the placebo for patients with mild to moderate COVID-19 in Phase 3 interim analysis.
...read full article on Benzinga
